Latest Dasatinib Stories
LONDON, August 11, 2014 /PRNewswire/ -- Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United
The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass.,
LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2,
Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug called ponatinib in a phase I clinical trial.
Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.
- A volcanic mudflow.